申请人:——
公开号:US20040236108A1
公开(公告)日:2004-11-25
The present invention is directed to carbocyclic hydrazino compounds that function as inhibitors of copper-containing amine oxidases commonly known as semicarbazide-sensitive amine oxidases (SSAO), including the human SSAO known as Vascular Adhesion Protein-1 (VAP-1). These SSAO inhibitors have therapeutic utility as drugs to treat conditions and diseases including, but not limited to, a number of inflammatory conditions and diseases (in particular chronic inflammatory conditions such as chronic arthritis, inflammatory bowel diseases, and chronic skin dermatoses), diseases related to carbohydrate metabolism and to aberrations in adipocyte differentiation or function and smooth muscle cell function, and vascular diseases. The novel compounds have the general formula:
1
or a pharmaceutically acceptable solvate, hydrate, or salt thereof, wherein R
1
to R
11
are as defined herein.
本发明涉及碳环酰肼化合物,其作为含铜胺氧化酶抑制剂,通常被称为半卡巴肼敏感胺氧化酶(SSAO)的抑制剂,包括人类SSAO,即血管黏附蛋白-1(VAP-1)。这些SSAO抑制剂具有治疗效用,可用作治疗条件和疾病的药物,包括但不限于多种炎症条件和疾病(特别是慢性炎症条件,如慢性关节炎,炎症性肠病和慢性皮肤皮疹),与碳水化合物代谢和脂肪细胞分化或功能异常以及平滑肌细胞功能和血管疾病有关的疾病。新型化合物的一般公式为:1或其药学上可接受的溶剂化合物、水合物或盐,其中R1到R11的定义如本文所述。